01What happened, in order
| Date | Event | What it changed |
|---|---|---|
| 2023 | FDA places many popular peptides in Category 2 of its interim 503A list | Compounding them became off-limits |
| 15–22 Apr 2026 | Twelve peptides leave Category 2 after nominations are withdrawn | Removal alone did not make them compoundable |
| 23–24 Jul 2026 | FDA's Pharmacy Compounding Advisory Committee narrowly backs six of seven peptides for the bulks list | Advisory only; FDA career staff had opposed |
| 28 Oct 2026 | HHS files the enforcement-discretion policy | Licensed compounders may proceed under ten conditions |
| 30 Oct 2026 | Published in the Federal Register; two-week comment window | Comments closed around 13 November |
| Next | FDA notice-and-comment rulemaking on the bulks list | The only route to a permanent listing; can take months to years |
02The six peptides covered
BPC-157
Covered with a defined identity and limited route, set out in the policy's appendix.
TB-500
Covered. Not the same molecule as full-length thymosin β4.
KPV
Covered. The tripeptide fragment of α-MSH.
MOTS-c
Covered. A mitochondria-derived peptide.
Semax
Covered. A synthetic ACTH(4–10) analogue.
Epitalon
Covered. A synthetic tetrapeptide.
03The ten conditions
All ten must be met for the policy to apply. Paraphrased from the published summary.
The substance must be listed in the policy's appendix.
Same identity and limited route of administration as the appendix specifies.
Bulk substance from an FDA-registered facility, with a valid certificate of analysis.
The original bulk manufacturer is FDA-registered and CGMP-compliant.
Serious adverse events are reported to FDA MedWatch.
“This is a compounded drug product. Not for resale.”
No blends or combination products.
Oral products need documentation that the formulation is adequately bioavailable.
The only device packaged with the product is an FDA 510(k)-cleared syringe.
All other FD&C Act requirements remain in force.
04What it does not do
- It does not approve any peptide or make any safety or efficacy finding.
- It does not add anything to the 503A bulks list; only rulemaking can.
- It does not cover blends, “stacks” or multi-ingredient products.
- It says nothing that makes selling research chemicals for human use lawful.
- It does not change anti-doping rules: sport bodies apply their own list.
- It is interim and non-binding, and HHS says it may revisit it if a safety or quality signal appears.
05What it means for research-use supply
Very little, directly. The policy is about prescription compounding by licensed pharmacies and physicians in the United States. Research-use-only supply is a separate lane with separate rules, and those rules depend on how a product is presented and to whom it is sold.
One indirect effect is worth noting: the policy sets a documentation bar (registered source, valid COA, CGMP manufacturer, single ingredient) that buyers in every lane will start to expect. We publish a certificate for every batch for the same reason.